Global Dihydropyridine Vasodilators Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08253473

Publication Date:

August 6, 2025

Pages:

120

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Dihydropyridine Vasodilators market size will reach US$ 1744 million by 2031.
Dihydropyridine vasodilators are a subclass of calcium channel blockers that primarily act on vascular smooth muscle to induce vasodilation by inhibiting L-type calcium channels. They are widely used in the treatment of hypertension and certain types of angina due to their potent ability to lower peripheral vascular resistance. Key drugs in this class include nifedipine, amlodipine, and felodipine, which are characterized by minimal cardiac effects compared to other calcium channel blockers.
United States market for Dihydropyridine Vasodilators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Dihydropyridine Vasodilators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Dihydropyridine Vasodilators is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Dihydropyridine Vasodilators players cover Bayer, Huanghai Pharma, Shyndec Pharma, Beijing Hongling Pharma, Ingenus Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒ihydropyridine Vasodilators Industry Forecast鈥� looks at past sales and reviews total world Dihydropyridine Vasodilators sales in 2024, providing a comprehensive analysis by region and market sector of projected Dihydropyridine Vasodilators sales for 2025 through 2031. With Dihydropyridine Vasodilators sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dihydropyridine Vasodilators industry.
This Insight Report provides a comprehensive analysis of the global Dihydropyridine Vasodilators landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dihydropyridine Vasodilators portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Dihydropyridine Vasodilators market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dihydropyridine Vasodilators and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dihydropyridine Vasodilators.
This report presents a comprehensive overview, market shares, and growth opportunities of Dihydropyridine Vasodilators market by product type, application, key players and key regions and countries.
Segmentation by Type:
Nifedipine
Iradipine
Felodipine
Nicardipine
Other
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Huanghai Pharma
Shyndec Pharma
Beijing Hongling Pharma
Ingenus Pharmaceutical
Sine Pharma
AstraZeneca
Lifeon Pharma
Teva
Nanjing Easeheal Pharma
Novartis
Baxter International
Hikma Pharmaceuticals
Astellas Pharma
Aguettant

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dihydropyridine Vasodilators Market Size (2020-2031)
2.1.2 Dihydropyridine Vasodilators Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Dihydropyridine Vasodilators by Country/Region (2020, 2024 & 2031)
2.2 Dihydropyridine Vasodilators Segment by Type
2.2.1 Nifedipine
2.2.2 Iradipine
2.2.3 Felodipine
2.2.4 Nicardipine
2.2.5 Other
2.3 Dihydropyridine Vasodilators Market Size by Type
2.3.1 Dihydropyridine Vasodilators Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Dihydropyridine Vasodilators Market Size Market Share by Type (2020-2025)
2.4 Dihydropyridine Vasodilators Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Dihydropyridine Vasodilators Market Size by Application
2.5.1 Dihydropyridine Vasodilators Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Dihydropyridine Vasodilators Market Size Market Share by Application (2020-2025)
3 Dihydropyridine Vasodilators Market Size by Player
3.1 Dihydropyridine Vasodilators Market Size Market Share by Player
3.1.1 Global Dihydropyridine Vasodilators Revenue by Player (2020-2025)
3.1.2 Global Dihydropyridine Vasodilators Revenue Market Share by Player (2020-2025)
3.2 Global Dihydropyridine Vasodilators Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Dihydropyridine Vasodilators by Region
4.1 Dihydropyridine Vasodilators Market Size by Region (2020-2025)
4.2 Global Dihydropyridine Vasodilators Annual Revenue by Country/Region (2020-2025)
4.3 Americas Dihydropyridine Vasodilators Market Size Growth (2020-2025)
4.4 APAC Dihydropyridine Vasodilators Market Size Growth (2020-2025)
4.5 Europe Dihydropyridine Vasodilators Market Size Growth (2020-2025)
4.6 Middle East & Africa Dihydropyridine Vasodilators Market Size Growth (2020-2025)
5 Americas
5.1 Americas Dihydropyridine Vasodilators Market Size by Country (2020-2025)
5.2 Americas Dihydropyridine Vasodilators Market Size by Type (2020-2025)
5.3 Americas Dihydropyridine Vasodilators Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dihydropyridine Vasodilators Market Size by Region (2020-2025)
6.2 APAC Dihydropyridine Vasodilators Market Size by Type (2020-2025)
6.3 APAC Dihydropyridine Vasodilators Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Dihydropyridine Vasodilators Market Size by Country (2020-2025)
7.2 Europe Dihydropyridine Vasodilators Market Size by Type (2020-2025)
7.3 Europe Dihydropyridine Vasodilators Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dihydropyridine Vasodilators by Region (2020-2025)
8.2 Middle East & Africa Dihydropyridine Vasodilators Market Size by Type (2020-2025)
8.3 Middle East & Africa Dihydropyridine Vasodilators Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Dihydropyridine Vasodilators Market Forecast
10.1 Global Dihydropyridine Vasodilators Forecast by Region (2026-2031)
10.1.1 Global Dihydropyridine Vasodilators Forecast by Region (2026-2031)
10.1.2 Americas Dihydropyridine Vasodilators Forecast
10.1.3 APAC Dihydropyridine Vasodilators Forecast
10.1.4 Europe Dihydropyridine Vasodilators Forecast
10.1.5 Middle East & Africa Dihydropyridine Vasodilators Forecast
10.2 Americas Dihydropyridine Vasodilators Forecast by Country (2026-2031)
10.2.1 United States Market Dihydropyridine Vasodilators Forecast
10.2.2 Canada Market Dihydropyridine Vasodilators Forecast
10.2.3 Mexico Market Dihydropyridine Vasodilators Forecast
10.2.4 Brazil Market Dihydropyridine Vasodilators Forecast
10.3 APAC Dihydropyridine Vasodilators Forecast by Region (2026-2031)
10.3.1 China Dihydropyridine Vasodilators Market Forecast
10.3.2 Japan Market Dihydropyridine Vasodilators Forecast
10.3.3 Korea Market Dihydropyridine Vasodilators Forecast
10.3.4 Southeast Asia Market Dihydropyridine Vasodilators Forecast
10.3.5 India Market Dihydropyridine Vasodilators Forecast
10.3.6 Australia Market Dihydropyridine Vasodilators Forecast
10.4 Europe Dihydropyridine Vasodilators Forecast by Country (2026-2031)
10.4.1 Germany Market Dihydropyridine Vasodilators Forecast
10.4.2 France Market Dihydropyridine Vasodilators Forecast
10.4.3 UK Market Dihydropyridine Vasodilators Forecast
10.4.4 Italy Market Dihydropyridine Vasodilators Forecast
10.4.5 Russia Market Dihydropyridine Vasodilators Forecast
10.5 Middle East & Africa Dihydropyridine Vasodilators Forecast by Region (2026-2031)
10.5.1 Egypt Market Dihydropyridine Vasodilators Forecast
10.5.2 South Africa Market Dihydropyridine Vasodilators Forecast
10.5.3 Israel Market Dihydropyridine Vasodilators Forecast
10.5.4 Turkey Market Dihydropyridine Vasodilators Forecast
10.6 Global Dihydropyridine Vasodilators Forecast by Type (2026-2031)
10.7 Global Dihydropyridine Vasodilators Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Dihydropyridine Vasodilators Forecast
11 Key Players Analysis
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Dihydropyridine Vasodilators Product Offered
11.1.3 Bayer Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Huanghai Pharma
11.2.1 Huanghai Pharma Company Information
11.2.2 Huanghai Pharma Dihydropyridine Vasodilators Product Offered
11.2.3 Huanghai Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Huanghai Pharma Main Business Overview
11.2.5 Huanghai Pharma Latest Developments
11.3 Shyndec Pharma
11.3.1 Shyndec Pharma Company Information
11.3.2 Shyndec Pharma Dihydropyridine Vasodilators Product Offered
11.3.3 Shyndec Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Shyndec Pharma Main Business Overview
11.3.5 Shyndec Pharma Latest Developments
11.4 Beijing Hongling Pharma
11.4.1 Beijing Hongling Pharma Company Information
11.4.2 Beijing Hongling Pharma Dihydropyridine Vasodilators Product Offered
11.4.3 Beijing Hongling Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Beijing Hongling Pharma Main Business Overview
11.4.5 Beijing Hongling Pharma Latest Developments
11.5 Ingenus Pharmaceutical
11.5.1 Ingenus Pharmaceutical Company Information
11.5.2 Ingenus Pharmaceutical Dihydropyridine Vasodilators Product Offered
11.5.3 Ingenus Pharmaceutical Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Ingenus Pharmaceutical Main Business Overview
11.5.5 Ingenus Pharmaceutical Latest Developments
11.6 Sine Pharma
11.6.1 Sine Pharma Company Information
11.6.2 Sine Pharma Dihydropyridine Vasodilators Product Offered
11.6.3 Sine Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Sine Pharma Main Business Overview
11.6.5 Sine Pharma Latest Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Information
11.7.2 AstraZeneca Dihydropyridine Vasodilators Product Offered
11.7.3 AstraZeneca Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 AstraZeneca Main Business Overview
11.7.5 AstraZeneca Latest Developments
11.8 Lifeon Pharma
11.8.1 Lifeon Pharma Company Information
11.8.2 Lifeon Pharma Dihydropyridine Vasodilators Product Offered
11.8.3 Lifeon Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Lifeon Pharma Main Business Overview
11.8.5 Lifeon Pharma Latest Developments
11.9 Teva
11.9.1 Teva Company Information
11.9.2 Teva Dihydropyridine Vasodilators Product Offered
11.9.3 Teva Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Teva Main Business Overview
11.9.5 Teva Latest Developments
11.10 Nanjing Easeheal Pharma
11.10.1 Nanjing Easeheal Pharma Company Information
11.10.2 Nanjing Easeheal Pharma Dihydropyridine Vasodilators Product Offered
11.10.3 Nanjing Easeheal Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Nanjing Easeheal Pharma Main Business Overview
11.10.5 Nanjing Easeheal Pharma Latest Developments
11.11 Novartis
11.11.1 Novartis Company Information
11.11.2 Novartis Dihydropyridine Vasodilators Product Offered
11.11.3 Novartis Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Novartis Main Business Overview
11.11.5 Novartis Latest Developments
11.12 Baxter International
11.12.1 Baxter International Company Information
11.12.2 Baxter International Dihydropyridine Vasodilators Product Offered
11.12.3 Baxter International Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Baxter International Main Business Overview
11.12.5 Baxter International Latest Developments
11.13 Hikma Pharmaceuticals
11.13.1 Hikma Pharmaceuticals Company Information
11.13.2 Hikma Pharmaceuticals Dihydropyridine Vasodilators Product Offered
11.13.3 Hikma Pharmaceuticals Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Hikma Pharmaceuticals Main Business Overview
11.13.5 Hikma Pharmaceuticals Latest Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Information
11.14.2 Astellas Pharma Dihydropyridine Vasodilators Product Offered
11.14.3 Astellas Pharma Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Astellas Pharma Main Business Overview
11.14.5 Astellas Pharma Latest Developments
11.15 Aguettant
11.15.1 Aguettant Company Information
11.15.2 Aguettant Dihydropyridine Vasodilators Product Offered
11.15.3 Aguettant Dihydropyridine Vasodilators Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Aguettant Main Business Overview
11.15.5 Aguettant Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂